DGAP-News: CALYPSO BIOTECH SA / Key word(s): Research Update/Study
Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases
Amsterdam, The Netherlands, 16 November 2020. Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15.
"CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan to investigate in multiple auto-immune diseases. CALY-002 has an unique mode of action which translates into potent biological activity in vivo and is expected to show superior clinical efficacy in patients", says Alain Vicari DVM, PhD, Chief Executive Officer of Calypso Biotech. "IL-15 is a key target in auto-immune diseases. IL-15 controls unique immune pathways such as Natural Killer cells and Memory T cells critically involved in disease onset and maintenance, as well as tissue destruction, in addition to its broad effect on inflammation", adds Yolande Chvatchko PhD, Chief Scientific Officer of Calypso Biotech.
Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. Celiac Disease and Eosinophilic Esophagitis are two diseases with high unmet medical need where IL-15 causes inflammation, and tissue destruction. "I am excited that this trial will inform about the safety, pharmacokinetic and pharmacodynamic of single and multiple administrations with CALY-002 in highly relevant populations." comments Josefin-Beate Holz, MD, Chief Medical Officer of Calypso Biotech.
More information on the trial can be found: https://clinicaltrials.gov/ct2/show/NCT04593251
About Eosinophilic Esophagitis and IL-15
About Calypso Biotech BV
16.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.